Carbonic anhydrase inhibitors like acetazolamide, methazolamide, and dichlorphenamide are sulfonamide derivatives that reversibly inhibit the carbonic anhydrase enzyme. This reduces hydrogen ion exchange and carbon dioxide reabsorption in the kidney, increasing sodium and bicarbonate excretion and producing alkaline urine. They are also used to treat glaucoma by decreasing aqueous humor production in the eye. Adverse effects can include vomiting and hyperchloremic acidosis due to chloride retention in the kidney.